{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dystrophic+Epidermolysis+Bullosa&page=2",
    "query": {
      "condition": "Dystrophic Epidermolysis Bullosa",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dystrophic+Epidermolysis+Bullosa&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T23:27:23.365Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04917887",
      "title": "Long-Term Follow-up Protocol",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa",
        "Dominant Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-05-25",
      "completion_date": "2028-05-25",
      "has_results": false,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 3,
      "location_summary": "Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida",
      "locations": [
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04917887"
    },
    {
      "nct_id": "NCT07011589",
      "title": "Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa (EB)",
        "Epidermolysis Bullosa Acquisita",
        "Recessive Dystrophic Epidermolysis Bullosa",
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Efgartigimod",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M. Peter Marinkovich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-07",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07011589"
    },
    {
      "nct_id": "NCT02178969",
      "title": "Short Term Observational Study in DEB Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 29,
      "start_date": "2014-06-24",
      "completion_date": "2015-02-23",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178969"
    },
    {
      "nct_id": "NCT05708677",
      "title": "A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "RDEB"
      ],
      "interventions": [
        {
          "name": "EB-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abeona Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-02-09",
      "completion_date": "2036-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 2,
      "location_summary": "Redwood City, California • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05708677"
    },
    {
      "nct_id": "NCT04213261",
      "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "FCX-007 (dabocemagene autoficel; see below for FCX-007 description)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Castle Creek Biosciences, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-06-09",
      "completion_date": "2037-07",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213261"
    },
    {
      "nct_id": "NCT03158662",
      "title": "Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-04-02",
      "completion_date": "2017-06-30",
      "has_results": false,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 1,
      "location_summary": "Cranbury, New Jersey",
      "locations": [
        {
          "city": "Cranbury",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03158662"
    },
    {
      "nct_id": "NCT04491604",
      "title": "Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa",
        "Dominant Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Topical Beremagene Geperpavec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-08-17",
      "completion_date": "2022-01-14",
      "has_results": true,
      "last_update_posted_date": "2023-02-17",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 3,
      "location_summary": "Rancho Santa Margarita, California • Stanford, California • Coral Gables, Florida",
      "locations": [
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04491604"
    },
    {
      "nct_id": "NCT03578029",
      "title": "Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Junctional Epidermolysis Bullosa",
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "RGN-137",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lenus Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-05-22",
      "completion_date": "2021-11-23",
      "has_results": false,
      "last_update_posted_date": "2022-08-22",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 5,
      "location_summary": "Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578029"
    },
    {
      "nct_id": "NCT06834035",
      "title": "Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Epidermolysis Bullosa Acquisita",
        "Dystrophic Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Immunoglobulin G",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M. Peter Marinkovich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2025-08-04",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834035"
    },
    {
      "nct_id": "NCT02670330",
      "title": "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101-6.0 cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 152,
      "start_date": "2015-06-09",
      "completion_date": "2018-09-03",
      "has_results": true,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-06-10T23:27:23.365Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670330"
    }
  ]
}